Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Dec 13 2022 | The Intersection of Diabetes, Chronic Kidney Disease and Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More Nov 14 2022 | Bridging the Gap: Advancing Health Equity in Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More Nov 7 2022 | Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Industry News In The News Industry Read More Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 29 Page 30 Page 31 Page 32 Current page 33 Page 34 Page 35 Page 36 Page 37 … Next page Next › Last page Last »
Dec 13 2022 | The Intersection of Diabetes, Chronic Kidney Disease and Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More
Dec 8 2022 | Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes Industry News In The News Industry Read More
Nov 14 2022 | Bridging the Gap: Advancing Health Equity in Heart Failure Patient News Heart Failure Awareness 365 Patient Resource Read More
Nov 7 2022 | Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease Industry News In The News Industry Read More
Nov 7 2022 | FARXIGA improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial Industry News Industry Read More
